A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer

LESSONS LEARNED. The combination of everolimus and low‐dose prednisone administered daily was hypothesized to prevent noninfectious pneumonitis (NIP) and mucositis, two common adverse events related to everolimus. Although mucositis was detected in only one case, all‐grade NIP occurred in four of ei...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncologist
Autores principales: Lolli, Cristian, Gallà, Valentina, Schepisi, Giuseppe, Barone, Domenico, Burgio, Salvatore Luca, Maugeri, Antonio, Vertogen, Bernadette, Amadori, Dino, De Giorgi, Ugo
Formato: Artigo
Lenguaje:Inglês
Publicado: AlphaMed Press 2017
Materias:
Clinical Trial Results
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5507652/
https://ncbi.nlm.nih.gov/pubmed/28546463
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0154
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares